First-in-class TAK1 kinase inhibitors were designed in a hit-to-lead program run in close cooperation between three partners, SARomics Biostructures, Red Glead Discovery, and Aqilion. This was made possible by an integrated approach, a fast design-make-test-analyze cycle, and applying structure-based drug design, compound synthesis, and evaluation.